Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for INSM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 24.51M
March 31, 2026 265.52M
December 31, 2025 389.41M
September 30, 2025 -762.23M
June 30, 2025 227.84M
March 31, 2025 80.41M
December 31, 2024 131.76M
September 30, 2024 -1.003B
June 30, 2024 -6.783M
March 31, 2024 295.32M
December 31, 2023 1.803M
September 30, 2023 7.147M
June 30, 2023 -274.16M
March 31, 2023 41.60M
December 31, 2022 20.31M
September 30, 2022 49.42M
June 30, 2022 -2.904M
March 31, 2022 -101.41M
December 31, 2021 -51.22M
September 30, 2021 -8.401M
June 30, 2021 -3.485M
March 31, 2021 -1.181M
December 31, 2020 -1.515M
September 30, 2020 -0.747M
June 30, 2020 -1.881M
Date Value
March 31, 2020 -2.679M
December 31, 2019 -13.04M
September 30, 2019 -14.59M
June 30, 2019 -10.61M
March 31, 2019 -4.028M
December 31, 2018 -4.751M
September 30, 2018 -1.851M
June 30, 2018 -2.847M
March 31, 2018 -5.365M
December 31, 2017 -1.70M
September 30, 2017 -0.447M
June 30, 2017 -0.437M
March 31, 2017 -0.417M
December 31, 2016 -0.772M
September 30, 2016 -1.30M
June 30, 2016 -1.54M
March 31, 2016 -0.588M
December 31, 2015 -0.407M
September 30, 2015 -0.853M
June 30, 2015 -0.93M
March 31, 2015 -1.264M
December 31, 2014 -1.527M
September 30, 2014 -2.919M
June 30, 2014 -0.564M
March 31, 2014 -0.331M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. -8.529M
Alnylam Pharmaceuticals, Inc. -363.46M
Biogen, Inc. -3.839B
Gilead Sciences, Inc. -10.35B
Agios Pharmaceuticals, Inc. 40.21M